Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

Fig. 3

Gene set enrichment analysis (GSEA) reveals ccRCC-enriched pathways. a Heatmap of pathway enrichment scores in ccRCC patient cohort 1. Shown are only signatures that were enriched in the cohort 1, defined by an enrichment score of ≥ 0.5 (marked by asterisks) in at least 80% of cohort patients. The signatures that were removed after comparison with the enrichment analyses in the proximal tubule cells are marked by blue asterisks. b Heatmap of enrichment in the proximal tubule cells with data taken from Young et al. [22]. Shown are only those signatures that were enriched in the cohort with a score of ≥ 0.5 (marked by asterisks) in at least 80% of cohort samples. Sources of gene signatures can be derived from the color bar to the left of the heatmap with the legend printed in a. Signatures that overlapped with enriched signatures of tumor tissues from cohort 1 are marked by blue asterisks. c Overlap of source genes of ccRCC-specific peptides and genes from ccRCC-enriched signatures

Back to article page